CASI Approved to Start Fourth China Phase II Trial of Cancer Drug

CASI Pharma, a US-China biopharma, received CFDA approval to extend the US Phase II trial of its lead molecule (ENMD-2076) in fibrolamellar carcinoma into China. CASI is already testing ENMD-2076 in three additional US-China Phase II trials for other indications. ENMD-2076 is an oral Aurora A/angiogenic kinase inhibitor that slows cell division and inhibits formation of new blood vessels. Headquartered in Maryland with a lab in Beijing, CASI in-licenses products for the China market, but the company is developing ENMD-2076 globally. More details.... Stock Symbol: (NSDQ: CASI) Share this with colleagues: // //